1. 1. Galanello R, Origa R.Review: Beta-thalassemia. Orphanet J Rare Dis.2010;5(11):1-15.
2.Rezaee AR,Banoei MM,Khalili E,Houshmand M. Beta-thalassemia in iran: new insight into the role of genetic admixture and migration. The Scientific World Journal. 2012;2012 :1-7.
3.Fahmey SS,Naguib HF, Abdelshafy SS, Alashry RE. Vascular endothelial growth factor in children with thalassemia major. Mediterr J Hematol Infect Dis.2013; 5(1).
4.Kosaryan M,Vahidshahi K,Karami H,Alizadeh Forootan M,Ahangari M . Survival of thalassemic patients referred to the Boo Ali Sina Teaching Hospital, Sari, Iran. Hemoglobin.2007;31(4): 453-462.
5.Musallam KM, Taher AT, Rachmilewitz EA. β-thalassemia intermedia: a clinical perspective. Cold Spring Harb perspect Med. 2012; 2(7):1-15.
6.Ekatherina S, Trudel M, Felfly H,Lemsaddek W, Garcia D, CloutierG. Vascular Endothelial Dysfunction in b-Thalassemia Occurs Despite Increased eNOS Expression and Preserved Vascular Smooth Muscle Cell Reactivity to NO. PLoS ONE. 2012; 7(6): e38089.
7.Butthep P, Rummavas S, Wisedpanichkij R, Jindadamrongwech S, Fucharoen S, Bunyaratvej A. Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumor necrosis factor in thalassemia. Am J Hematol. 2002; 70(2): 100-106.
8.Shitrit, D, Hannah T, Arielc K, Carinac L, Ariella Sulkes B Sh, et al. Correlation of vascular endothelial growth factor with the severity of thalassemia intermedia. Blood Coagul Fibrinolysis. 2008; 19(7): 611-614.
9.Kofler NM, Simons M. Angiogenesis versus arteriogenesis: neuropilin 1 modulation of VEGF signaling. F1000Prime Rep. 2015; 3(7): eCollection.
10.Dunst J, Becker A, Lautenschläger Ch,Markau S,Becker H, Fischer K ,et al., Anemia and elevated systemic levels of vascular endothelial growth factor (VEGF). Strahlenther Onkol. 2002;178(8): 436-441.
11.Olgar S,Kara A, Hicyilmaz H,Balta N,Canatan D. Evaluation of angiogenesis with vascular endothelial growth factor in patients with thalassemia major. Pediatr Int. 2010; 52(2): 247-251.
12.Dunst J, Pigorsch Sh, Hfinsgen H, Hintner I, Lautenschlfiger Ch,Becker A. Low hemoglobin is associated with increased serum levels of vascular endothelial growth factor (VEGF) in cancer patients. Strahlenther Onkol. 1999; 175(3): 93-96.
13.Van Royen N,Piek JJ, Schaper W,Bode Ch, Buschmann I. Arteriogenesis: mechanisms and modulation of collateral artery development. J Nucl Cardiol. 2001; 8(6) 687-693.
14. Rapisarda A, M.G., Role of the VEGF/VEGFR axis in cancer biology and therapy. Guidance Molecules in Cancer and Tumor Angiogenesis. 2012; 114: 237-255.
15.Risau W. Mechanisms of angiogenesis. Nature. 1997; 386(6626): 671-674.
16.Daniel B, Joel B, Leila M, Rabih CH. Current insights on the biology and clinical aspects of VEGF regulation. Vasc Endovascular surg. 2008; 42(6):517-30.
17.Stone J, Itin A,Alon T,Pe'Er J,Gnessin H,Chan-Ling T, et al. Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia. J Neurosci.1995; 15(7): 4738-4747.
18.Park CC ,Bissell MJ,Barcellos-Hoff MH.The influence of the microenvironment on the malignant phenotype. Molecular medicine today. 2000; 6(8): 324-329.
19.Ramakrishnan S, Anand V, Roy S. Vascular Endothelial growth factor signaling in hypoxia and Inflammation. J Neuroimmune Pharmacology. 2014; 9(2): 142-160.
|